RNAi


Also found in: Medical, Acronyms, Encyclopedia, Wikipedia.

RNAi

abbr.
RNA interference
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Mentioned in ?
References in periodicals archive ?
'The ORION-11 results represent a landmark event for Alnylam and RNAi therapeutics.
By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality.
The "RNAi - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
According to Alnylam, monthly administration of the investigational RNAi therapeutic can potentially decrease induced liver ALAS1 levels in a sustained manner by a significant extent.
RNAi therapeutics company Alnylam Pharmaceuticals Inc (Nasdaq:ALNY) on Monday announced an exclusive agreement in Israel to commercialise ONPATTRO as well as other investigational therapeutics under its RNAi portfolio through Medison Pharma, Israel's leading commercial partner for innovative pharmaceuticals.
"We are committed to advancing new RNA-targeted therapeutics, like RNAi and antisense, to patients with high unmet medical need in China," said Liang Zicai, founder and chairman of Ribo.
Keywords: Spodoptera litura; RNAi; RNAi machinery; Sid; Systemic RNAi response
Ultimately, RNAi technology is a giant in the world of drug discovery and the development of therapeutic treatments and Altogen Labs offers quality services that allow for the successful delivery of stable, functional siRNA or microRNA to a target tissue.
The acquisition includes assignment of certain patents and patent applications owned or controlled by Novartis related to RNAi therapeutics, an exclusive license in the RNAi field to other patents and patent applications owned or controlled by Novartis, assignment of a third party license, three pre-clinical RNAi candidates, and other related assets.
In 12 chapters, genetics, molecular biomedicine, and other researchers from around the world detail advances in basic applied RNA interference (RNAi) medical research and applications in RNAi-based therapies.